Live · 13 Sep 2026 SPX 7,656.98 +0.86% NDX 29,368.44 +0.91% VIX 15.84 -11.21% GOLD 4,390.00 +0.58% CL 99.99 -2.43% BTC 77,135.67 +0.74%
NAS100 29,368 +0.91% S&P 7,657 +0.86% GOLD $4,390 +0.58% BTC $77,136 +0.74% VIX 15.84 −11.21% live tape · as of 10:31 UTC
Vol. II · No. 256Sunday, 13 September 2026
TTitan Protect
The Screen · Healthcare

Oncotelic Therapeutics, Inc.

OTLC · OQB · USD · Market cap $14M

PASS · Titan Ethical
0.03 USD

At the last full screen
2026-09-07

Screened 2026-09-07 · the tape above runs as of 10:31 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed

The Label · The Season, Not the Day

This name holds its markup label.

Oncotelic Therapeutics, Inc. holds its Markup at $0.03. The statistical read favours the buyers, held for 8 days.

As held on the ledger · 2026-09-07
PhaseMarkup
Quantitative stateThe statistical read favours the buyers, held for 8 days
Price at the screen$0.03
Valuation0.05 trailing · N/A forward price to earnings
Values screenPASS
Beta-0.24
The Workings

Five Screens, Shown in Full

Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.

TestFigureLimitWhat it meansStatus
Business activity Permissible Core business clean Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. Pass
Debt load 0.00% Below 33% Interest-bearing debt is just 0.0% of its assets, well under the one-third ceiling: it does not run on borrowed money. Pass
Interest-bearing cash 0.00% Below 33% Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit. Pass
Receivables 0.00% Below 49% Money owed to the company is 0.0% of assets, under the 49% limit. Pass
Revenue purity 0.00% Below 5% Only 0.0% of revenue comes from non-compliant sources, under the 5% line. Pass

Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.

The Business, in Plain Words
The fundamentals · plain-English read
Trailing P/E0.1xvery cheap relative to earnings
EPS, trailing0.59
EPS, forward0.00
Profit margin98,998.0%highly profitable on every dollar of sales
Return on equity182.6%an exceptional return on shareholder capital
FCF yield-0.40%
Debt to equity0.05minimal debt: a conservative balance sheet
Current ratio0.08below 1: short-term bills exceed liquid assets
Beta-0.24barely tracks the market's swings
Short interest, float0.03%
52-week range0.02 - 0.11
Market cap$14M

The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market.

Plain-English interpretation of our own screen data. Analysis, not advice.

Where & How to Trade

OTLC trades on OQB. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.

The Dated Journal · Newest First, Never Edited

Every Entry, As Written

2026-09-08 Markup · changed $0.03 -25.0% Entry 5

The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 25.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it A. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 17%. Our forward projection puts the odds of a 10% gain over the next month near 34%.

2026-08-08 Distribution · changed $0.04 -20.0% Entry 4

The framework has shifted from accumulation to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 20.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it A. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 17%. Our forward projection puts the odds of a 10% gain over the next month near 34%.

2026-07-18 Accumulation $0.05 +0.0% Entry 3

The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it A. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 17%. Our forward projection puts the odds of a 10% gain over the next month near 34%.

2026-07-03 Accumulation $0.05 +0.0% Entry 2

The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows good risk-adjusted returns.

2026-07-02 Accumulation $0.05 Entry 1

The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows good risk-adjusted returns.

Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.

Related Securities · Others in OTLC's Space

Screened names in the same industry · explore each on its own page.

The Insider Ledger · Form 4 Filings, As Filed
Most recent filings · OTLC
DateInsiderTitleTypeSharesValue
2025-07-10 TRIEU VUONG Chief Executive Officer 198,737 $10,334
2025-01-31 TRIEU VUONG Chief Executive Officer 346,844 $9,712
2024-11-22 TRIEU VUONG Chief Executive Officer 298,499 $8,627
2024-08-23 TRIEU VUONG Chief Executive Officer 500,000 $10,000

Public filings, recorded as found. The full tape lives at Insider Intelligence.

What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $0.04 +25.0% · $1,250 +25.0%
2 months $0.03 +66.7% · $1,667 +66.7%
3 months $0.04 +25.0% · $1,250 +25.0%
6 months $0.09 -44.4% · $556 -44.4%
1 year $0.06 -16.7% · $833 -16.7%
2 years $0.04 +25.0% · $1,250 +25.0%
3 years $0.03 +66.7% · $1,667 +66.7%
5 years $0.26 -80.8% · $192 -80.8%

Historical returns from market close data. Past performance does not guarantee future results.

The Ledger's Promise

This entry now belongs to the ledger. Whatever OTLC does next, these words stay.

Oncotelic Therapeutics, Inc. · OTLC · Markup · $0.03
Recorded 2026-09-07 · before the outcome · scored mechanically

Membership

Thirteen thousand names carry this page. One desk keeps them honest.

Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.

Join the desk

Screening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.

Get our weekly market brief free.